Simeprevir/sofosbuvir

Simeprevir/sofosbuvir Reactions 1704, p342 - 2 Jun 2018 Hyperbilirubinaemia and severe asthenia: 2 case reports In a prospective, observational cohort study of 204 patients, two patients [ages and sexes not stated] were described, who developed severe asthenia or hyperbilirubinaemia during treatment with simeprevir and sofosbuvir for chronic hepatitis C [durations of treatments to reactions onsets not stated]. The patients with chronic hepatitis C started receiving treatment with oral sofosbuvir 400mg daily and oral simeprevir 150mg daily. Subsequently, one patient developed severe asthenia and second patient developed severe hyperbilirubinaemia with a bilirubin level of 10 mg/dL. The treatment with simeprevir and sofosbuvir was stopped in the patient having hyperbilirubinaemia, after which an improvement was noted [not all outcomes stated]. Author comment: [Asthenia] was the most common adverse effect, reported by 46 patients (22.5%). It was mild in 38 patients, moderate in seven and severe in one. The causes that led to the suspension of treatment were. . .severe hyperbilirubinaemia (10 mg/dL). In one patient it was decided to suspend treatment for this reason, with subsequent improvement. Moreno-Planas JM, et al. Influence of baseline MELD score in the efficacy of treatment of hepatitis C with simeprevir and sofosbuvir. Enfermedades Infecciosas Y Microbiologia Clinica 36: 277-283, No. 5, May 2018. Available from: URL: http://doi.org/10.1016/j.eimc.2017.05.001 [Spanish; Summarised from a translation] - Spain 803323161 0114-9954/18/1704-0001/$14.95 Adis © 2018 Springer International Publishing AG. All rights reserved Reactions 2 Jun 2018 No. 1704 http://www.deepdyve.com/assets/images/DeepDyve-Logo-lg.png Reactions Weekly Springer Journals

Simeprevir/sofosbuvir

Reactions Weekly , Volume 1704 (1) – Jun 2, 2018
Free
1 page

Loading next page...
1 Page
 
/lp/springer_journal/simeprevir-sofosbuvir-Jo5Slx3UJY
Publisher
Springer International Publishing
Copyright
Copyright © 2018 by Springer International Publishing AG, part of Springer Nature
Subject
Medicine & Public Health; Drug Safety and Pharmacovigilance; Pharmacology/Toxicology
ISSN
0114-9954
eISSN
1179-2051
D.O.I.
10.1007/s40278-018-46985-y
Publisher site
See Article on Publisher Site

Abstract

Reactions 1704, p342 - 2 Jun 2018 Hyperbilirubinaemia and severe asthenia: 2 case reports In a prospective, observational cohort study of 204 patients, two patients [ages and sexes not stated] were described, who developed severe asthenia or hyperbilirubinaemia during treatment with simeprevir and sofosbuvir for chronic hepatitis C [durations of treatments to reactions onsets not stated]. The patients with chronic hepatitis C started receiving treatment with oral sofosbuvir 400mg daily and oral simeprevir 150mg daily. Subsequently, one patient developed severe asthenia and second patient developed severe hyperbilirubinaemia with a bilirubin level of 10 mg/dL. The treatment with simeprevir and sofosbuvir was stopped in the patient having hyperbilirubinaemia, after which an improvement was noted [not all outcomes stated]. Author comment: [Asthenia] was the most common adverse effect, reported by 46 patients (22.5%). It was mild in 38 patients, moderate in seven and severe in one. The causes that led to the suspension of treatment were. . .severe hyperbilirubinaemia (10 mg/dL). In one patient it was decided to suspend treatment for this reason, with subsequent improvement. Moreno-Planas JM, et al. Influence of baseline MELD score in the efficacy of treatment of hepatitis C with simeprevir and sofosbuvir. Enfermedades Infecciosas Y Microbiologia Clinica 36: 277-283, No. 5, May 2018. Available from: URL: http://doi.org/10.1016/j.eimc.2017.05.001 [Spanish; Summarised from a translation] - Spain 803323161 0114-9954/18/1704-0001/$14.95 Adis © 2018 Springer International Publishing AG. All rights reserved Reactions 2 Jun 2018 No. 1704

Journal

Reactions WeeklySpringer Journals

Published: Jun 2, 2018

References

You’re reading a free preview. Subscribe to read the entire article.


DeepDyve is your
personal research library

It’s your single place to instantly
discover and read the research
that matters to you.

Enjoy affordable access to
over 18 million articles from more than
15,000 peer-reviewed journals.

All for just $49/month

Explore the DeepDyve Library

Search

Query the DeepDyve database, plus search all of PubMed and Google Scholar seamlessly

Organize

Save any article or search result from DeepDyve, PubMed, and Google Scholar... all in one place.

Access

Get unlimited, online access to over 18 million full-text articles from more than 15,000 scientific journals.

Your journals are on DeepDyve

Read from thousands of the leading scholarly journals from SpringerNature, Elsevier, Wiley-Blackwell, Oxford University Press and more.

All the latest content is available, no embargo periods.

See the journals in your area

DeepDyve

Freelancer

DeepDyve

Pro

Price

FREE

$49/month
$360/year

Save searches from
Google Scholar,
PubMed

Create lists to
organize your research

Export lists, citations

Read DeepDyve articles

Abstract access only

Unlimited access to over
18 million full-text articles

Print

20 pages / month

PDF Discount

20% off